Acute phase results from storm, a multicountry observational study of bipolar disorder treatment and outcomes

Psychiatria Danubina

Volumn 19, Issue 4, 2007, Pages 282-295

  Treuer, Tamás ^a   Oruč, Lilijana ^b   Loza, Naser ^c   El Saidi, Mohammed A ^d   Kovacs, Zoltán ^e   Akkaya, Cengiz ^f   Gülseren, Şeref ^g   Şaylan, Mete ^h   Colman, Samuel A ⁱ   Harrison, Gavan A ⁱ  

^a Lilly Area Medical Center   (Austria)

^b KLINICKI CENTAR UNIVERZITETA U SARAJEVU   (Bosnia and Herzegovina)

^c Behman Hospital   (Egypt)

^d Department of Orthopedic Surgery   (Saudi Arabia)

^e Martinska Fakultna Nemocnica   (Slovakia)

^f ULUDAG UNIVERSITY   (Turkey)

^g ATATURK TRAINING AND RESEARCH HOSPITAL   (Turkey)

^h Eli Lilly   (Turkey)

ⁱ ELI LILLY AUSTRALIA PTY LTD   (Australia)

Author keywords

Antipsychotic; Bipolar disorder; Mania; Observational study; Olanzapine; STORM

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CARBAMAZEPINE; CHLORPROMAZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; HALOPERIDOL; LITHIUM SALT; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; TRANQUILIZER; VALPROIC ACID;

ADULT; AKATHISIA; AMNESIA; ARTICLE; BIPOLAR DISORDER; BIPOLAR MANIA; BOSNIA AND HERZEGOVINA; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL PRACTICE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONCENTRATION LOSS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DIZZINESS; DRUG WITHDRAWAL; DYSTONIA; EGYPT; FEMALE; GASTROINTESTINAL SYMPTOM; HAMILTON SCALE; HOSPITAL PATIENT; HUMAN; INSOMNIA; LINEAR REGRESSION ANALYSIS; LOGISTIC REGRESSION ANALYSIS; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MENSTRUATION DISORDER; MONOTHERAPY; MULTICENTER STUDY; NOCTURIA; OBSERVATIONAL STUDY; OUTPATIENT; PARKINSONISM; POLYURIA; PROGNOSIS; PSYCHOSIS; REMISSION; SAUDI ARABIA; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SLOVAKIA; SLOVENIA; SYMPTOM; TARDIVE DYSKINESIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TREMOR; TURKEY (REPUBLIC); WEIGHT GAIN;

ACUTE DISEASE; ADMINISTRATION, ORAL; ADULT; ANTICONVULSANTS; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BIPOLAR DISORDER; COHORT STUDIES; CROSS-CULTURAL COMPARISON; DRUG THERAPY, COMBINATION; DRUG UTILIZATION; FEMALE; HUMANS; LONG-TERM CARE; MALE; MIDDLE AGED; PERSONALITY INVENTORY; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; TREATMENT OUTCOME;

EID: 36448974917     PISSN: 03535053     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. [APA] American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth edition, Text Revision (DSM-IV-TR). Washington, DC: American Psychiatric Association 2000.
2. Dando S, Tohen M. Olanzapine - relapse prevention following mania. J Psychopharmacol 2006; 20:31-8.
3. Dossenbach M, Erol A, el Mahfoud Kessaci M, Shaheen MO, Sunbol MM, Boland J, et al. IC-SOHO Study Group. Effectiveness of antipsychotic treatments for schizophrenia: Interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol. J Clin Psychiatry 2004; 65:312-21 .
4. Faries D, Ascher-Svanum H, Zhu B, Olson B. Psychiatric hospitalisations in the long-term naturalistic treatment of schizophrenia patients with risperidone, olanzapine, or quetiapine. Proceedings of the US Psychiatric and Mental Health Congress; 2004 Nov 18-21; San Diego, CA. Irvine, CA: CME LLC; 2004.
5. Gonzalez-Pinto A, Ballesteros J, Aldama A, Perez de Heredia JL, Gutierrez M, Mosquera F et al. Principal components of mania. J Affect Disord 2003;76:95-102.
6. Haro JM, van Os J, Vieta E, Reed C, Lorenzo M, Goetz I. Evidence for three distinct classes of 'typical', 'psychotic' and 'dual' mania: results from the EMBLEM study. Acta Psychiatr Scand 2006;113:112-20.
7. Hellewell JS. A review of the evidence for the use of antipsychotics in the maintenance treatment of bipolar disorders. J Psychopharmacol 2006; 20:39-45.
8. Hernan MA, Robins JM. Estimating causal effects from epidemiological data. J Epidemiol Community Health 2006; 60:578-86.
9. Jones RM, Thompson C, Bitter I. A systematic review of the efficacy and safety of second generation antipsychotics in the treatment of mania. Eur Psychiatty 2006; 21:1-9.
10. Kinon BJ, Basson BR, Gilmore JA, Tollefson GD. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J Clin Psychiatry 2001; 62:92-100.
11. Littrell KH, Petty RG, Wolf NM. Olanzapine: a 5-year perspective. Expert Rev Neurother 2006; 6:811-21.
12. McCormack PL, Wiseman LR. Olanzapine: a review of its use in the management of bipolar I disorder. Drugs 2004; 64:2709-26.
13. Mitchell PB, Malhi GS. The expanding pharmacopoeia for bipolar disorder. Annu Rev Med 2002; 53:173-88.
14. Perlis RH, Welge JA, Vornik LA, Hirschfeld RM, Keck PE Jr. Atypical antipsychotics in the treatment of mania: a meta-analysis of randomized, placebo-controlled trials. J Clin Psychiatry 2006; 67:509-16.
15. Robins JM, Hernan MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology 2000; 11:550-60.
16. Spearing MK, Post RM, Leverich GS, Brandt D, Nolen W. Modification of the Clinical Global Impressions (CGI) Scale for use in bipolar illness (BP): the CGI-BP. Psychiatry Res 1997; 73:159-71.
17. Stensland MD, Ranjan R, Faries D, Zhu B, Houston J. The effectiveness of olanzapine vs. divalproex in clinical practice: A 1-year study of the treatment of mixed, manic, and hypomanic episodes of bipolar disorder. Proceedings of the Annual Meeting of the American Psychiatric Association; 2006 May 25; Toronto, Canada. Arlington, VA: American Psychiatric Association; 2006.
18. Storosum JG, Fouwels A, Gispen-de Wied CC, Wohlfarth T, van Zwieten BJ, van den, Brink W. How real are patients in placebo-controlled studies of acute manic episode? Eur Neuropsychopharmacol 2004; 14:319-23.
19. Surja AA, Tamas RL, El Mallakh RS. Antipsychotic medications in the treatment of bipolar disorder. Curr Drug Targets 2006; 7:1217-24.
20. Tunis SL, Kinon BJ, Faries DE, Ascher-Svanum H, Nyhuis AW, Aquila R. Cost-effectiveness of olanzapine asfirst-line treatment for schizophrenia: results from a randomized, open-label, one-year trial. Value Health 2006; 9:77-89.
21. Wada K, Sasaki T, Jitsuiki H, Yoshimura Y, Erabi H, Hada Y, et al. Manic/hypomanic switch during acute antidepressant treatment for unipolar depression. J Clin Psychopharmacol 2006; 26:512-15.
22. Young RC, Biggs JT, Ziegler VT, Meyer DA. A rating scale for mania: reliability, validity, and sensitivity. Br J Psychiatry 1978; 133:429-35.